公开(公告)号：US20130090612A1

公开(公告)日：2013-04-11

申请号：US13688019

申请日：2012-11-28

申请人： Eugene de Juan, JR. ,  Yair Alster ,  Cary J. Reich ,  K. Angela MacFarlane ,  Janelle Chang ,  Jose D. Alejandro

发明人： Eugene de Juan, JR. ,  Yair Alster ,  Cary J. Reich ,  K. Angela MacFarlane ,  Janelle Chang ,  Jose D. Alejandro

IPC分类号： A61F9/00

CPC分类号： A61F9/0017 ,  A61B17/00234 ,  A61K9/0051 ,  A61K47/34 ,  A61L27/025 ,  A61L27/16

摘要： A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

公开(公告)号：US08377122B2

公开(公告)日：2013-02-19

申请号：US12694691

申请日：2010-01-27

申请人： Thomas A. Silvestrini ,  Eugene de Juan, Jr.

发明人： Thomas A. Silvestrini ,  Eugene de Juan, Jr.

IPC分类号： A61F2/14

CPC分类号： A61F9/00781 ,  A61F2210/0019

摘要： Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.

公开(公告)号：US08277830B2

公开(公告)日：2012-10-02

申请号：US13252998

申请日：2011-10-04

申请人： Eugene de Juan, Jr. ,  Yair Alster ,  Kathleen Cogan Farinas ,  Hanson S. Gifford, III ,  K. Angela MacFarlane ,  Cary J. Reich ,  Michael Barrett ,  Randolph E. Campbell ,  Douglas Sutton

发明人： Eugene de Juan, Jr. ,  Yair Alster ,  Kathleen Cogan Farinas ,  Hanson S. Gifford, III ,  K. Angela MacFarlane ,  Cary J. Reich ,  Michael Barrett ,  Randolph E. Campbell ,  Douglas Sutton

IPC分类号： A61M37/00 ,  A61M31/00

CPC分类号： G01N33/558 ,  A61F9/0017 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/57 ,  A61K31/573 ,  A61K31/58 ,  A61K38/385 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/55 ,  Y10T29/49826

摘要： A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

公开(公告)号：US08167939B2

公开(公告)日：2012-05-01

申请号：US13245802

申请日：2011-09-26

申请人： Thomas A. Silvestrini ,  Eugene de Juan, Jr.

发明人： Thomas A. Silvestrini ,  Eugene de Juan, Jr.

IPC分类号： A61F2/14

CPC分类号： A61F9/00781 ,  A61F2210/0019

摘要： Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.

公开(公告)号：US07998497B2

公开(公告)日：2011-08-16

申请号：US11695545

申请日：2007-04-02

申请人： Eugene de Juan, Jr. ,  Stephen Boyd ,  Cary Reich ,  Alan Rapacki ,  Hanson S. Gifford, III ,  Mark Deem

发明人： Eugene de Juan, Jr. ,  Stephen Boyd ,  Cary Reich ,  Alan Rapacki ,  Hanson S. Gifford, III ,  Mark Deem

IPC分类号： A61F2/02

CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/0026 ,  A61F9/00772 ,  A61F9/00781 ,  A61F2220/0008 ,  A61F2250/0067 ,  A61F2250/0087 ,  A61K9/00 ,  A61K9/0017 ,  A61K9/06 ,  A61K31/215 ,  A61K31/216 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/573 ,  A61K47/34 ,  A61L31/16

摘要： Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug core. The exposed surface(s) of the drug core may contact a tear or tear film fluid and release the therapeutic agent at therapeutic levels over a sustained period when the implant is implanted for use. The implant may include a retention element to retain the drug core and sheath body near the punctum, optionally comprising a shape memory alloy that can resiliently expand. An occlusive element may be attached to the retention element to at least partially occlude tear flow through the canalicular lumen.

摘要翻译： 用于插入患者泪点的植入装置，系统和方法可任选地包括药物核心和设置在药物核心上方的鞘体。 药物核心包括可递送到眼睛中的治疗剂，护套限定药物核心的至少一个暴露表面。 药物核心的暴露表面可以接触泪液或泪膜流体，并且当植入物植入使用时在持续的时间内以治疗水平释放治疗剂。 植入物可以包括保持元件，以将药物核心和鞘体保持在泪点附近，任选地包括可弹性膨胀的形状记忆合金。 闭塞元件可以连接到保持元件以至少部分地封闭穿过小管腔的泪液流动。

公开(公告)号：US20110098629A1

公开(公告)日：2011-04-28

申请号：US12970482

申请日：2010-12-16

申请人： Eugene de Juan, JR. ,  Stephen Boyd ,  Mark E. Deem ,  Hanson S. Gifford, III ,  Dan Rosenman

发明人： Eugene de Juan, JR. ,  Stephen Boyd ,  Mark E. Deem ,  Hanson S. Gifford, III ,  Dan Rosenman

IPC分类号： A61F9/00

CPC分类号： A61F9/00781 ,  A61B34/70 ,  A61B90/00 ,  A61F2/14 ,  A61F2/142 ,  A61F9/0008 ,  A61F9/0017 ,  A61F9/007 ,  A61F9/00736 ,  A61F9/0133 ,  A61F11/00 ,  A61F2250/0001 ,  A61F2250/0096 ,  A61F2250/0097 ,  A61K9/0051 ,  A61M27/002 ,  A61M2202/04 ,  A61M2210/0612

摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

摘要翻译： 方法和装置适于植入眼睛。 在眼睛的角膜中形成切口，并且通过切口将分路插入眼睛的前房。 分流器包括流体通道。 所述分流器沿着从所述前房通过所述眼睛的巩膜刺入所述脉管外空间的路径通过并且定位在第一位置，使得所述流体通道的第一部分与所述前房连通，并且所述流体通道的第二部分 与脉管外空间连通，以在脉络膜上空间和前房之间提供流体通道。

公开(公告)号：US20110028983A1

公开(公告)日：2011-02-03

申请号：US12898630

申请日：2010-10-05

申请人： Thomas A. Silvestrini ,  Eugene de Juan, JR.

发明人： Thomas A. Silvestrini ,  Eugene de Juan, JR.

IPC分类号： A61F9/007

CPC分类号： A61F9/00781 ,  A61F2210/0019

摘要： Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.

公开(公告)号：US20100114309A1

公开(公告)日：2010-05-06

申请号：US12521543

申请日：2007-12-21

申请人： Eugene de Juan, JR. ,  Cary J. Reich ,  Stephen Boyd ,  Hanson S. Gifford ,  Mark Deem

发明人： Eugene de Juan, JR. ,  Cary J. Reich ,  Stephen Boyd ,  Hanson S. Gifford ,  Mark Deem

IPC分类号： A61F2/16

CPC分类号： A61F9/0017 ,  A61F9/00772 ,  A61F9/00781 ,  A61K9/0051

摘要： An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.

摘要翻译： 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中，以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中，眼睛的屈光性可以包括近视，远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如，治疗剂可以包括睫状肌麻痹症，其包括阿托品，环戊二酸酯，琥珀酰胆碱，同质素，东莨菪碱或托品酰胺中的至少一种。 在许多实施例中，保持元件可以附接到结构以沿着天然组织表面保持结构。

公开(公告)号：US20070191863A1

公开(公告)日：2007-08-16

申请号：US11615810

申请日：2006-12-22

申请人： Eugene De Juan ,  Stephen Boyd ,  Mark Deem ,  Hanson Gifford ,  Dan Rosenman

发明人： Eugene De Juan ,  Stephen Boyd ,  Mark Deem ,  Hanson Gifford ,  Dan Rosenman

IPC分类号： A61F11/00

CPC分类号： A61F9/00781 ,  A61B34/70 ,  A61B90/00 ,  A61F2/14 ,  A61F2/142 ,  A61F9/0008 ,  A61F9/0017 ,  A61F9/007 ,  A61F9/00736 ,  A61F9/0133 ,  A61F11/00 ,  A61F2250/0001 ,  A61F2250/0096 ,  A61F2250/0097 ,  A61K9/0051 ,  A61M27/002 ,  A61M2202/04 ,  A61M2210/0612

摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

摘要翻译： 方法和装置适于植入眼睛。 在眼睛的角膜中形成切口，并且通过切口将分路插入眼睛的前房。 分流器包括流体通道。 所述分流器沿着从所述前房通过所述眼睛的巩膜刺入所述脉管外空间的路径通过并且定位在第一位置，使得所述流体通道的第一部分与所述前房连通，并且所述流体通道的第二部分 与脉管外空间连通，以在脉络膜上空间和前房之间提供流体通道。

公开(公告)号：US07137994B2

公开(公告)日：2006-11-21

申请号：US09904201

申请日：2001-07-11

申请人： Eugene de Juan, Jr. ,  Eric T. Lee

发明人： Eugene de Juan, Jr. ,  Eric T. Lee

IPC分类号： A61F2/16

CPC分类号： A61F2/1664 ,  A61F2/1616

摘要： Featured is an injectable intraocular lens system including an insertion and injection device and an injectable intraocular lens. In its broadest aspects, the injectable intraocular lens is a deflated flexible bag that is disposed within the insertion and injection device prior to insertion into the eye. In use a portion of the insertion and injection device is inserted into the eye and the flexible bag is deployed out from an aperture in the inserted portion into the eye. Following deployment, the insertion and injection device injects an optical medium, such as a liquid, into the interior of the flexible bag, thereby inflating the bag. In an illustrative embodiment, the amount of medium being injected is selected so that the inflated bag provides the desired corrective power to the intraocular lens so formed. Following injection of the medium, the interconnection between the insertion and injection device and the interior of the flexible bag is broken and a seal is formed so as to keep the medium within the flexible bag interior.